Renalytix Says Positive Study Results Published for KidneyIntelX

- Advertisement -


by Michael Susin

- Advertisement -
- Advertisement -

Renalytics said Tuesday that the American Journal of Nephrology has published positive study results for its flagship product, KidneyIntelX.

The UK-based diagnostics group said the peer-reviewed findings suggest that KidneyIntelX is an effective risk monitoring tool to assess the effectiveness and response to new treatments for patients with diabetes and chronic kidney disease who are at risk for cardiovascular events. is at risk.

- Advertisement -

The company said that clinical trials were conducted on 1,325 participants with diabetic kidney disease. This represents the third published, peer-reviewed clinical validation study and the first multinational study for KidneyIntelX, it said.

Chief Medical Officer Michael Donovan said, “This positive study is further demonstration that KidneyIntelX can be used to provide the most effective care pathway for physicians, so patients get the right treatment, at the right time, at the right time.” “

Shares were up 10.0 pence, or 1.8%, at 560.0 pence at 1404 GMT.

Write to Michael Susin at [email protected]

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox